Palantir Technologies on Thursday said it was teaming up with a nuclear deployment company to develop an artificial ...

Galapagos unveils plan to split, hiving off its drugs unit. Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its drug development and cell therapy operations.

After FDA says no, Bayer bags EU nod for twice-yearly Eylea. Bayer has been given a leg up in the competitive market for VEGF therapies used to treat eye diseases with a new EU approval for Eylea 8mg.